Melissa Leichter Announces The Newly FDA Approved Subcutaneous Prophylactic Treatment for Hemophilia A or B
Melissa Leichter, Rare Disease Executive, Novo Nordisk, shared a proud announcement post on LinkedIn:
”Today marks an exciting step forward for the hemophilia community. The FDA has approved our new subcutaneous prophylactic treatment for patients aged 12 and older living with hemophilia A or B.
This approval builds on our earlier indication for people living with hemophilia with inhibitors and reflects our continued commitment to expanding access and reimagining care across the hemophilia landscape.
Behind this milestone is a team of passionate, driven individuals who work tirelessly to bring innovative solutions to life. I am incredibly proud to be part of this journey—one that’s focused on delivering better options and more control for people navigating life with hemophilia. Thank you to the entire team who has contributed to this great achievement. Your dedication makes a real difference.”
Melissa Leichter proudly shares news on FDA Approvement for Alhemo.
Latest news in the field of Hemophilia Management featured in Hemostasis Today.
-
Aug 2, 2025, 04:14WFH in Madagascar: Advancing National Bleeding Disorder Guidelines and Governance
-
Aug 2, 2025, 04:03Cesar Garrido: Continued WFH Support Secured in Ecuador
-
Aug 2, 2025, 03:50FDA Approves Novo Nordisk Prophylactic Treatment for Hemophilia A and B
-
Aug 2, 2025, 03:40Glenn Pierce on Overcoming Barriers to Gene Therapy in Hemophilia Care
-
Aug 2, 2025, 03:21CVC Associated Thrombosis Prevention and Management: New International Guidelines Reviewed
-
Aug 2, 2025, 04:31Acute VTE in Women: Continue Contraception, Select the Right Anticoagulant
-
Aug 1, 2025, 13:11Isabelle Mahé Shares an Insight from APICAT Study: Use of Apixaban in Cancer Associated Thrombosis
-
Jul 31, 2025, 16:12Samin Mohsenian Shares the Final Open Access Version: Ob/Gyn Complications and Congenital Fibrinogen Disorders
-
Jul 31, 2025, 15:45Tzu-Fei Wang: To Anticoagulate or Not To Anticoagulate—That Is The Question
-
Jul 31, 2025, 15:12Wolfgang Miesbach: Protecting Liver Health in Bleeding Disorders
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Jul 14, 2025, 16:39Dr. Philipp Bücke: MRI Proven as No.1 Choice for Accurate TIA Diagnosis
-
Jul 13, 2025, 16:05EMA and HMA Mark a Key Step with 1st AI Observatory Report
-
Jul 31, 2025, 15:37Sano Genetics: “Unreasonable” Leadership with Benny Sorenson of Hemab
-
Jul 28, 2025, 12:53Zambia’s Hemophilia Prophylaxis Success
-
Jul 26, 2025, 16:14Cesar Garrido: Forging Strong Partnerships on WHA78 ''Global Health Equity'' Event
-
Jul 23, 2025, 15:34Don't Miss the Hemophilia B Virtual Event on July 29 – Sign Up Now!
-
Jul 23, 2025, 11:05Haemnet Gives Voice to Parents Facing the Challenges of Childhood Bleeding Disorders